## FORSCHUNGSINSTITUT FÜR KLINISCHE MEDIZINTECHNIK Silberhälden 6

D - 71 679 Asperg / Württ.

## **Certification**

**Nebulizer Performance Test Result** 

**Brand**: Plusmed / Type: pM-N01

OBL Manufacturer: TRIMPEKS ITH. IHR. TUR. ve TIC. A.S., Istanbul, Turkey

It is hereby certified, that the above listed heavy duty piston type nebulizer, *Plusmed pM-N01*, has been tested by Rossmax Int. Ltd under the subsequent review of the FIMT (Asperg, Germany) regarding

- (1) the aerosol particle size distribution
- (2) nebulization output rate (including medication delivery)
- (3) effective residual volume.

Tests have been provided according to the standards and regulations given with EN13544 – 2009 (Respiratory Therapy Equipment-Part 1: Nebulizing Systems and their Components) and the FDA Reviewer Guidance for Nebulizers, Metered Dose Inhalers, Spacers and Actuators-1993.

The <u>aerosol particle size</u> was tested by two methods, the Malvern Spraytec Reflectometry Technique (A), as well as the Marble 298 Cascade Impactor Method (B).

The *Plusmed pM-N01* complies with the medically requested mass median aerodynamic diameter MMAD < 5 [ $\mu$ m] as well as with the Rossmax specification of MMAD < 3 [ $\mu$ m]: In (B) MMAD is found as being 2.07 [ $\mu$ m] with a fine particle dose FPD of 81.4 %, in (A) the Dv(50) is found as being < 3.3 [ $\mu$ m] in open valve condition and Dv(50) < 3.5 [ $\mu$ m] in closed valve condition.

The <u>nebulization rate</u>, including the application of ipratropium bromide, flixotide, terbutaline sulphate and salbutamol resulted in a flow > 0.65 [ml/min] in open valve condition and a flow of > 0.23 [ml/min] in closed valve condition.

The residual volume has been < 0.68 [ml] in both closed and open valve status.

The nebulizer **Plusmed pM-N01** fully qualifies for the intended medical application and is especially consistent with a sustained therapeutic use on patients.

Asperg, January 26, 2015

FORSCHUNGSINSTITUT FÜF KLINISCHE MEDIZINTECHNIK

FAX: +49 - 7141 - 200-220

The Director of the FIMT (Asperg).